Free tool
Diagnostics stocks
We cover 33 companies grouped under the Diagnostics theme. The median market value in the group is $1.11B. Across the group, the median move over the past trading day is −0.58%. 64% of the 33 with a 200-day average trade above it. Price change over the past year runs from −80.3% to +164.4% across the middle 80 percent of the group, with a median of −6.5%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
33 of 150 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| NTRA | Natera, Inc. | $338.45 | +34.19% | +47.90% | +107.59% | Nov 5, 2026 |
| LH | Labcorp Holdings Inc. | $335.72 | +6.84% | +33.74% | +21.14% | Nov 3, 2026 |
| DGX | Quest Diagnostics Incorporated | $245.00 | +3.84% | +42.24% | +38.12% | Oct 20, 2026 |
| GH | Guardant Health, Inc. | $170.92 | +19.01% | +68.00% | +169.17% | Oct 28, 2026 |
| TEM | Tempus AI, Inc. | $68.48 | +59.63% | +9.81% | −6.49% | Nov 3, 2026 |
| QGEN | Qiagen N.V. | $43.36 | +2.55% | −4.05% | −9.65% | Nov 4, 2026 |
| CAI | Caris Life Sciences, Inc. | $26.82 | +72.03% | −0.59% | −29.83% | Nov 4, 2026 |
| BLLN | BillionToOne, Inc. | $96.22 | −28.00% | +7.76% | −11.68% | Nov 5, 2026 |
| ADPT | Adaptive Biotechnologies Corporation | $26.16 | +16.16% | +64.42% | +101.70% | Nov 4, 2026 |
| VCYT | Veracyte, Inc. Common Stock | $44.29 | −20.41% | +4.48% | +54.81% | Nov 3, 2026 |
| GRAL | GRAIL, Inc. | $79.59 | +23.55% | −10.44% | +136.66% | Nov 11, 2026 |
| WGS | GeneDx Holdings Corp. | $90.29 | +45.90% | −31.76% | −30.11% | Oct 27, 2026 |
| CDNA | CareDx, Inc. | $50.96 | +42.55% | +166.25% | +283.45% | Nov 3, 2026 |
| NEOG | Neogen Corporation | $11.70 | +27.31% | +67.14% | +103.83% | Oct 8, 2026 |
| NEO | NeoGenomics, Inc. | $17.37 | +29.63% | +47.70% | +145.34% | Oct 27, 2026 |
| PSNL | Personalis, Inc. | $17.08 | +43.77% | +117.58% | +257.32% | Nov 3, 2026 |
| OPK | OPKO Health, Inc. | $1.51 | −8.48% | +18.90% | +6.34% | Oct 28, 2026 |
| CSTL | Castle Biosciences, Inc. | $34.08 | +42.65% | −11.57% | +52.96% | Nov 2, 2026 |
| QDEL | QuidelOrtho Corporation | $14.91 | −10.56% | −48.19% | −46.31% | Nov 5, 2026 |
| FLGT | Fulgent Genetics, Inc. | $19.81 | +0.92% | −22.59% | −8.46% | Nov 6, 2026 |
| MYGN | Myriad Genetics, Inc. | $3.12 | −41.35% | −49.19% | −47.39% | Nov 2, 2026 |
| BDSX | Biodesix, Inc. | $30.60 | +45.51% | +373.68% | +225.53% | Nov 3, 2026 |
| OSUR | OraSure Technologies, Inc. | $3.71 | −7.71% | +55.88% | +11.08% | Nov 4, 2026 |
| XGN | Exagen Inc. | $7.67 | +72.36% | +26.99% | −19.69% | Nov 10, 2026 |
| LUCD | Lucid Diagnostics Inc. | $0.97 | +6.20% | −13.33% | −22.96% | Nov 11, 2026 |
| IMDX | Insight Molecular Diagnostics Inc. | $4.30 | −6.72% | −39.94% | +73.39% | Nov 9, 2026 |
| SERA | Sera Prognostics, Inc. | $2.09 | +2.96% | −30.33% | −26.41% | Nov 16, 2026 |
| MDXH | MDxHealth SA | $0.76 | +83.97% | −77.96% | −84.51% | Nov 12, 2026 |
| PAVM | PAVmed Inc. | $5.32 | −1.12% | −27.42% | −63.21% | Nov 12, 2026 |
| CODX | Co-Diagnostics, Inc. | $1.25 | −11.35% | −77.52% | −87.22% | Nov 16, 2026 |
| CDIO | Cardio Diagnostics Holdings, Inc. | $1.93 | +23.72% | −32.04% | −48.46% | Nov 6, 2026 |
| VNRX | VolitionRx Limited | $0.34 | −60.09% | −93.72% | −97.47% | Nov 12, 2026 |
| REVB | Revelation Biosciences, Inc. | $0.96 | −8.00% | −70.63% | −91.25% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.